Y-Intercept (HK)’s BioAtla BCAB Stock Holding History

Y-Intercept (HK)’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,237	Closed	-$222K	–	1315
2024 Q2	$222K	Buy	+3,237	New	+$385K	0.01%	1145

Other funds holding BCAB

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Y-Intercept (HK)'s BCAB Position: Q3 2024 in Review

Y-Intercept (HK) sold out of BioAtla (BCAB) in Q3 2024, closing a stake of 3,237 shares — an estimated $222K sold.

Y-Intercept (HK) first reported a position in BCAB in Q2 2024 and held it in 1 quarter. The position peaked at $222K in Q2 2024. 63 funds tracked by Wall St. Rank hold BCAB as of Q3 2024.

Y-Intercept (HK) reported no remaining BioAtla position as of Q3 2024 after selling out during the quarter.
Y-Intercept (HK) sold 3,237 BioAtla shares in Q3 2024, an estimated $222K.
Y-Intercept (HK) first reported a position in BioAtla in Q2 2024 and held it in 1 quarter.
Y-Intercept (HK)'s BioAtla position peaked at $222K in Q2 2024.
63 funds tracked by Wall St. Rank held BioAtla as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.